Loading clinical trials...

Your health journey, clearly organized.

Legal

Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia | Clinical Trials | Clareo Health

Back to search

COMPLETEDPhase 3

Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia

Counteracting Risperidone-Induced Hyperprolactinemia in Youths

NCT00799383•Chadi A. Calarge

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Risperidone-induced Hyperprolactinemia

Interventions

Calcium and Vitamin D

Placebo

Locations

United States

Locations (1)

The University of Iowa

Iowa City, Iowa, United States

Key Dates

Start Date

November 1, 2008

Primary Completion Date

March 1, 2014

Completion Date

March 1, 2014

Last Updated

December 26, 2017

Sponsors

Lead Sponsor

Chadi A. Calarge

Collaborators

National Institute of Mental Health (NIMH)
Children's Miracle Network

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 26, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions